Zobrazeno 1 - 6
of 6
pro vyhledávání: '"GHANSHYAM GHELANI"'
Autor:
Alanna Glidden Siegenthaler MD, Ghanshyam Ghelani MBBS, Amy Brady DO, Taylor Loon MBBCh, Bhaskara Reddy Madhira MBBS
Publikováno v:
Journal of Investigative Medicine High Impact Case Reports, Vol 11 (2023)
The occurrence of hemolytic anemia in patients with active SARS-CoV-2 infection has been documented in medical literature. While relatively uncommon, there have been instances where this condition presents as a Coombs-negative hemolytic anemia. In th
Externí odkaz:
https://doaj.org/article/5598e8a2de104d88a847ebff83eee224
Autor:
Maroun Bou Zerdan, Prashanth Ashok Kumar, Dulce M. Barrios, Alanna Glidden, Dayana Nasr, Stephanie Niforatos, Ghanshyam Ghelani, Jennifer Leibovitch, Sandy Nasr, Binod KC, Mulham Ombada, Farzam Khokhar, Bhavya Poudyal, Jenish Bhandari, Myera Shahnawaz, Stephen Graziano, Seah H. Lim
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
BackgroundMany co-existing medical conditions may affect the outcome in patients treated with immune checkpoint inhibitors for advanced cancer. There is currently not any information on whether metabolic syndrome (MetS) impacts the clinical outcome i
Externí odkaz:
https://doaj.org/article/553e90450542467bb054b954b836a303
Autor:
GHANSHYAM GHELANI, Anupa Mandava, Maroun BouZerdan, Radhika Mehta, Abirami Sivapiragasam, Roger Wong
Background Immune checkpoint inhibitors are extensively employed in the management of various solid cancers. Our study aims to assess the potential prognostic and predictive value of peripheral blood biomarkers, as well as their correlation with adve
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e0937122b746bedb263d539aa2af7daf
https://doi.org/10.21203/rs.3.rs-2920882/v1
https://doi.org/10.21203/rs.3.rs-2920882/v1
Autor:
Dayana, Nasr, Prashanth Ashok, Kumar, Maroun Bou, Zerdan, Ghanshyam, Ghelani, Dibyendu, Dutta, Stephen, Graziano, Seah H, Lim
Publikováno v:
Life Sciences. 310:121126
Immunotherapy was first investigated as a therapeutic option for treating cancer more than a century ago. During this period, it has gone through numerous disappointments when the successes obtained in the laboratory were not matched clinically. Howe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::342d9e1d7985b6e575f186f0790fb08a
https://doi.org/10.1016/j.lfs.2022.121126
https://doi.org/10.1016/j.lfs.2022.121126
Publikováno v:
Blood. 126:5341-5341
Background: Immunoglobulin M-producing multiple myeloma (IgM MM) accounts for less than 1% of all myeloma cases. Because the disorder is rare,its clinical characteristics and long-term prognosis remain unknown. Hyperviscosity occurs from pathologic c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::57cf13c526c3ddb203127c7ae34fed0e
https://doi.org/10.1182/blood.v126.23.5341.5341
https://doi.org/10.1182/blood.v126.23.5341.5341
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.